U.S. Patent and Trademark Office Invalidates Pharmacyclics Patent Asserted Against BeiGene

Contributed by: Business Wire

Logo

Tags

Oncology

Professional Services

Patent Law

Health

Genetics

Pharmaceutical

Biotechnology

USPTO decision

More Like This

(Graphic: Business Wire)

BeiGene Unveils Proposed Name Change to BeOne Medicines, Reaffirming Its Mission to Unite Global Community Against Cancer

U.S. FDA Approves Tablet Formulation of BeOne’s BRUKINSA® for All Approved Indications

BeOne Medicines' biologics manufacturing facility and clinical R&D center in Hopewell, NJ.

BeOne Medicines Launches Following Redomiciliation to Switzerland, Marking a New Chapter in Global Oncology

BeiGene Showcases Strength of Hematology Portfolio at EHA 2025 with New Data Highlighting BRUKINSA’s Leadership and Next-Generation Innovation

BeOne Medicines Receives Positive CHMP Opinion for Tablet Formulation of BRUKINSA®

BeiGene to Present at the RBC Capital Markets Global Healthcare Conference

BeiGene Announces First Quarter 2025 Financial Results and Business Updates

BeiGene Highlights Innovative Hematology Portfolio Across B-cell Malignancies at ASH 2024